卵巢子宫内膜异位囊肿粘连程度及相关因素分析

Objective To investigate the relationship between degree of endometrioma adhesions and clinical feature, surgical treatment and postoperative recurrence. Methods From Jan 2003 to Mar 2008, 662 patients with endometrioma undergoing laparoscopic ovarian endometrioma excision in Peking Union Medical College Hospital were studied retrospectively. All patients were classified into four groups according to the extent of adhesions: 31 cases in none adhesions group, 123 cases in mild adhesions group (filmy thickness, avascular, easily separated adhesions), 310 cases in moderate adhesions group (less than a half of ovary was adjacent to dense thickness adhesions which was difficult to separate, or above a half of ovary were adjacent to filmy thickness adhesions) and 198 cases in severe adhesions group (above a half of ovary was adjacent to dense thickness, well vascularized adhesions which was difficult to separate, and always involved the other pelvic organs, observed angiogenesis). The comparison of degree, characteristics, period of pain, lab test, surgical management and postoperative recurrence was performed among those above groups. In the mean time, risk factors and multinomial logistic regression were analyzed. Results (1)Clinical characteristics: The incidence of patients with dysmenorrhea, dyspareunia, straining feeling in anus, chronic pelvic pain and the level of CA125 (>35 kU/L) was remarkably higher in moderate-to-severe adhesion groups than in none-to-mild adhesions groups (P=0.000, 0.000, 0.001, 0.006 and 0.000, respectively). Infertility rate were significantly higher in severe adhesions group(15.7%,31/198) than none adhesions group(3.2%,1/31), mild adhesions group(11.4%,14/123) and moderate adhesions group(9.7%,30/310, OR=1.728, P<0.05).(2)Operating time and blood loss: Operating time of each groups was as followed: (37±15) min in none adhesions group, (42±19) min in mild adhesions group, (50±20) min in moderate adhesions group and (63±22) min in severe adhesion group. Blood loss was (23±12) ml in none adhesion group, (31±27) ml in mild adhesion group, (40±32) ml in moderate adhesion group and (70±67) ml in severe adhesions group. Thicker adhesions result in longer operation time and more blood loss. (3)Combined with other disease: The ratio of patients who combined with adenomyosis or deeply infiltrating endometriosis in moderate-to-severer adhesion groups was higher than patients in none-to-mild adhesions groups (OR=3.466, P=0.000). (4) Postoperative recurrence: It was categorized into recurrence of pain and cyst. Moderate-to-severe adhesions was related to higher recurrence rate of pain (OR=1.685,P=0.046), but was irrelevant to recurrence of cyst. Conclusion The more extent of endometrioma adhesions was related to severer pelvic pain symptoms, longer operating time and more blood loss. Postoperative pain recurrence rate was observed in moderate-to-severe adhesion group. Extent of adhesions was irrelevant to cyst recurrence.     

骨髓间充质干细胞分化为皮肤附属器细胞的初步实验研究

目的探讨骨髓间充质干细胞(marrowmesenchymalstemcells,MSCs)分化为创面皮肤附属器细胞的可能性,及其参与创面修复的可能机制。方法无菌条件下取Wistar大鼠股骨骨髓细胞,密度梯度离心分离、纯化MSCs,体外培养扩增后,用BrdU标记细胞。另于同种雄性Wistar大鼠背部正中,制备1cm×1cm全厚皮肤缺损创面模型,将BrdU标记的1×106/mlMSCs从阴茎静脉输注,术后第3天与第7天切取创面组织,行BrdU免疫组织化学单染色,以及BrdU和广谱角蛋白免疫组织化学双染色。结果BrdU阳性细胞出现在创面皮下组织、皮脂腺、毛囊和骨髓腔中。免疫组织化学双染色结果显示,皮脂腺和毛囊有BrdU阳性细胞,同时表达广谱角蛋白。结论创面愈合过程中,MSCs归巢并参与创面修复;在实验性全身皮肤缺损创面微环境下,MSCs可分化为皮肤附属器细胞。     

护理本科生创造性思维培训

[目的]对护理本科生实施创造性思维训练,并评估该训练方案的有效性。[方法]对20名护理本科生实施为期3个月的创造性思维培训,并与24名不接受培训者进行对照。采用《创造性思维练习》量表对培训前后学生的创造性思维进行测定。[结果]培训后实验组较对照组的创造性思维总分及流畅性得分有显著提高(P<0.05);变通性和独创性得分无统计学意义(P>0.05)。[结论]创造性思维培训对提高护理本科生创造性思维总体有效,其中对提高创造性思维的流畅性效果显著。     

粉防己碱对野百合碱致大鼠肺动脉构形重建的逆转作用

以野百合碱复制Ｗｉｓｔａｒ大鼠肺动脉高压模型，用特殊染色方法观察粉防已碱对野百合碱致大鼠肺动脉构形重建的逆转作用，结果表明粉防已碱可选择性的降低野百合碱诱导的大鼠肺动脉高压的作用，并明显地逆转肺血管及肺组织损伤，降低肺动脉高压和右心室肥大，对体循环压力无影响     

载瘤动脉闭塞术治疗颅内巨大动脉瘤的探讨

目的总结和探讨脑血管造影和载瘤动脉闭塞在治疗颅内巨大动脉瘤上的作用及特点。方法60例颅内巨大动脉瘤患者,根据其脑血管造影的特点采取血管内介入方法[可脱式球囊和(或)弹簧圈]闭塞载瘤动脉近端53例、闭塞载瘤动脉两端后孤立动脉瘤7例;其中23例闭塞前先行颅内-外血管搭桥术。结果出院时Rankin评分分级:单纯血管内介入治疗组37例中轻残3例,合并颅内-外血管搭桥术组23例中死亡1例、重残2例。1-6年的影像学随访动脉瘤无复发。结论血管内介入结合颅内-外血管搭桥术闭塞载瘤动脉是治疗颅内巨大动脉瘤的方法之一。     

重组人血小板源性生长因子增加细胞外信号调节激酶磷酸化促进糖尿病大鼠全层皮肤缺损创面愈合

目的 在体观察重组人血小板源性生长因子（recombinant human platelet—derived growth factor，rhPDGF）促进糖尿病大鼠全层皮肤缺损创面修复可能涉及的细胞和分子机制，研究其可能涉及的信号通路。方法 26只糖尿病大鼠，每只动物背部制备4个全层皮肤缺损创面，选取其中52个创面，随机分成3组，即对照组，创面自然愈合；rhPDGF治疗组，创面rhPDGF用量为7．0μg／cm^2；赋形剂组，创面用等量赋形剂凝胶。观察治疗后3、7和14d创面肉芽形成、胶原沉积、再上皮化速率以及炎性细胞浸润情况，并采用免疫荧光和免疫组织化学技术观察创面周围和创面修复细胞内细胞外信号调节激酶1／2（extracellular signal—regulated kinase1／2，ERK1／2）磷酸化和增殖细胞核抗原（proliferative cell nuclear antigen，PCNA）的表达。结果 组织学观察，rhPDGF治疗组创面可见大量炎性细胞浸润，毛细血管胚芽及成纤维细胞明显多于另两组（P〈0．05）；胶原沉积明显，肉芽组织生长活跃，创面收缩显著，与对照组比较差异有统计学意义（P〈0．05）。免疫学研究显示，应用rhPDGF7～14d后，rhPDGF治疗组ERK1／2明显强于对照组和赋形剂组（P〈0．05）；且损伤后3～7d rhPDGF治疗组修复细胞PCNA的表达明显高于对照组和赋形剂组（P〈0．05）。结论 rhPDGF促糖尿病大鼠刨面愈合的作用部分是通过ERK1／2信号通路的磷酸化来完成的。     

膝交叉韧带重建术的护理配合

随着社会经济的不断发展，由于交通及运动损伤引起的膝关节损伤目趋增多。交叉韧带是维持膝关节稳定的重要结构，韧带的断裂会引起关节不稳，若时间长会发展成创伤性关节炎，严重影响病人的工作与生活。膝交叉韧带重建术，尤其在关节镜监视下重建是近年来发展起来的一项新技术，通过手术能有效地恢复关节的稳定与功能，但手术的效果优劣在很大程度上取决于手术技术及术中医护配合的好坏。2000年7月-2003年7月，我院共行膝交叉韧带重建术236例，现将护理配合报告如下。     

微创清除术治疗高血压脑出血35例的临床观察

目的观察应用微创清除术救治高血压脑出血的临床疗效。方法对68例高血压脑出血患者采用随机分成内科组(33例,采用控制血压治疗脑水肿等方法)和微创组(35例,采用微创清除术治疗)。采用格拉斯神经功能缺损评分量表及日常生活能力量表评分比较两组的近期(1个月)和远期(6个月)疗效。结果微创组近期优良率(60%)和远期良好率以上(70.3%)高于内科组(30.3%、46.2%%),差异有显著性(P<0.05,P<0.01);微创组近期死亡率(14.3%)明显低于内科组(54.5%),差异有显著性(P<0.01)。结论高血压脑出血采用微创清除术疗效优于内科治疗。     

Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention.

This study evaluated the safety and efficacy of batroxobin in treating hyperfibrinogenemia for secondary stroke prevention. Patients with ischemic stroke or transient ischemic attack (TIA) were measured for plasma fibrinogen levels. Selected participants had concomitant hyperfibrinogenemia (plasma fibrinogen > or = 3.0 g/l). Patients enrolled between 1 July 2003 and 31 December 2004 were treated with batroxobin; patients enrolled between 1 January 2002 and 30 June 2003 were treated without batroxobin. Batroxobin was administered intermittently via intravenous injection at 3-monthly intervals. Patients in both groups were followed for 1 year. Any cerebrovascular events and suspected adverse events were recorded. In total, 112 ischemic stroke/TIA patients with concomitant hyperfibrinogenemia were enrolled, 52 being treated with batroxobin and 60 without batroxobin. Six patients (11.5%) with batroxobin and 16 patients (26.7%) without batroxobin had recurrent cerebral ischemic events during follow-up. Stroke/TIA recurrence in patients without batroxobin was higher than that in patients with batroxobin (P < 0.05). Two patients with batroxobin and two patients without batroxobin developed hemorrhagic stroke during follow-up. There were five deaths (9.6%) in the batroxobin group, and seven deaths (11.7%) in the nonbatroxobin group during follow-up (P > 0.05). Intermittent intravenous injection of batroxobin can efficiently reduce the risk for stroke/TIA recurrence in patients with concomitant hyperfibrinogenemia.